ABUS Arbutus Biopharma
- 3.870
- -0.090-2.27%
- 3.920
- +0.050+1.29%
Arbutus Biopharma News
JMP Securities Maintains Arbutus Biopharma(ABUS.US) With Buy Rating, Maintains Target Price $5
Arbutus Biopharma Is Maintained at Buy by Jefferies
Jefferies Maintains Arbutus Biopharma(ABUS.US) With Buy Rating, Raises Target Price to $7
Buy Rating Affirmed for Arbutus Biopharma Amid Positive Legal and Clinical Developments
JMP Securities Maintains Market Outperform on Arbutus Biopharma, Raises Price Target to $5
Arbutus Biopharma Analyst Ratings
H.C. Wainwright Maintains Arbutus Biopharma(ABUS.US) With Buy Rating, Maintains Target Price $5
Chardan Capital Maintains Arbutus Biopharma(ABUS.US) With Buy Rating, Maintains Target Price $4
Buy Rating Justified by Arbutus Biopharma's Strong Financials and Focused Clinical Strategy
JMP Securities Maintains Arbutus Biopharma(ABUS.US) With Buy Rating, Raises Target Price to $5
Arbutus Biopharma: Strategic Focus and Pipeline Promise Drive Buy Rating
Arbutus Biopharma Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Arbutus Biopharma, Maintains $5 Price Target
Arbutus Biopharma Analyst Ratings
Analysts Have Conflicting Sentiments on These Healthcare Companies: Ultragenyx Pharmaceutical (RARE), Hologic (HOLX) and Arbutus Biopharma (ABUS)
Arbutus Biopharma Analyst Ratings
Analysts Have Conflicting Sentiments on These Healthcare Companies: Arbutus Biopharma (ABUS), Neurocrine (NBIX) and Bausch Health Companies (BHC)
Analysts Are Bullish on Top Healthcare Stocks: Arbutus Biopharma (ABUS), Lemaitre Vascular (LMAT)
Arbutus Biopharma Analyst Ratings
JMP Securities Reiterates Market Outperform on Arbutus Biopharma, Maintains $4 Price Target
Analysis
Price Target
No Data
No Data